Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Changes in Stockholders' Equity

v3.23.3
Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Treasury stock
Additional Paid-in Capital
Accumulated Deficit
Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2021   96,752,000        
Beginning balance at Dec. 31, 2021 $ 65,277 $ 10   $ 264,944 $ (199,325) $ (352)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Exercise of stock options, net of vesting of restricted shares (in shares)   23,000        
Exercise of stock options, net of vesting of restricted shares 16     16    
Release of restricted stock (in shares)   1,409,000        
Issuance of common stock under the 2018 employee stock purchase plan (in shares)   96,000        
Issuance of common stock under the 2018 employee stock purchase plan 116     116    
Sales of common stock, net of issuance costs (in shares)   2,193,000        
Sales of common stock, net of issuance cost 3,654     3,654    
Issuance of common stock in connection with acquisition of Lyte Technology, Inc. (in shares)   848,000        
Issuance of common stock in connection with acquisition of Lyte Technology, Inc. 1,814     1,814    
Stock-based compensation expense 2,113     2,113    
Cumulative translation adjustment (201)         (201)
Net loss (40,006)       (40,006)  
Ending balance at Sep. 30, 2022 32,783 $ 10   272,657 (239,331) (553)
Ending balance (in shares) at Sep. 30, 2022   101,321,000        
Beginning balance (in shares) at Jun. 30, 2022   98,137,000        
Beginning balance at Jun. 30, 2022 35,693 $ 10   267,465 (231,313) (469)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Release of restricted stock (in shares)   527,000        
Sales of common stock, net of issuance costs (in shares)   2,193,000        
Sales of common stock, net of issuance cost 3,654     3,654    
Issuance of common stock in connection with acquisition of Lyte Technology, Inc. (in shares)   464,000        
Issuance of common stock in connection with acquisition of Lyte Technology, Inc. 689     689    
Stock-based compensation expense 849     849    
Cumulative translation adjustment (84)         (84)
Net loss (8,018)       (8,018)  
Ending balance at Sep. 30, 2022 $ 32,783 $ 10   272,657 (239,331) (553)
Ending balance (in shares) at Sep. 30, 2022   101,321,000        
Beginning balance (in shares) at Dec. 31, 2022 103,153,337 103,153,000        
Beginning balance at Dec. 31, 2022 $ 24,881 $ 10 $ 0 275,562 (250,219) (472)
Beginning balance (in shares) at Dec. 31, 2022 0   0      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Exercise of stock options, net of vesting of restricted shares (in shares)   95,000        
Exercise of stock options, net of vesting of restricted shares $ 58     58    
Release of restricted stock (in shares)   2,693,000        
Release of restricted stock 1 $ 1        
Issuance of restricted stock for earned bonus and consulting fees (in shares)   522,000        
Issuance of restricted stock for earned bonus and consulting fees 379     379    
Issuance of common stock under the 2018 employee stock purchase plan (in shares)   93,000        
Issuance of common stock under the 2018 employee stock purchase plan 47     47    
Sales of common stock, net of issuance costs (in shares)   19,107,000        
Sales of common stock, net of issuance cost 6,996 $ 2   6,994    
Common Stock issued upon conversion of 2022 Promissory Note (in shares)   3,399,000        
Common Stock issued upon conversion of 2022 Promissory Note 800     800    
Stock-based compensation expense 3,658     3,658    
Cumulative translation adjustment 9         9
Treasury stock repurchase (in shares)     (507,000)      
Treasury stock repurchase (502)   $ (502)      
Net loss (29,772)       (29,772)  
Ending balance at Sep. 30, 2023 $ 6,555 $ 13 $ (502) 287,498 (279,991) (463)
Ending balance (in shares) at Sep. 30, 2023 128,555,644 129,062,000        
Ending balance (in shares) at Sep. 30, 2023 (506,500)   (507,000)      
Beginning balance (in shares) at Jun. 30, 2023   107,565,000        
Beginning balance at Jun. 30, 2023 $ 17,908 $ 11 $ (502) 279,837 (261,012) (426)
Beginning balance (in shares) at Jun. 30, 2023     (507,000)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Release of restricted stock (in shares)   557,000        
Release of restricted stock 0          
Sales of common stock, net of issuance costs (in shares)   17,392,000        
Sales of common stock, net of issuance cost 6,001 $ 2   5,999    
Common Stock issued upon conversion of 2022 Promissory Note (in shares)   3,399,000        
Common Stock issued upon conversion of 2022 Promissory Note 800     800    
Issuance of common stock in lieu of consulting fees (in shares)   149,000        
Issuance of common stock in lieu of consulting fees 33     33    
Stock-based compensation expense 829     829    
Cumulative translation adjustment (37)         (37)
Treasury stock repurchase 0          
Net loss (18,979)       (18,979)  
Ending balance at Sep. 30, 2023 $ 6,555 $ 13 $ (502) $ 287,498 $ (279,991) $ (463)
Ending balance (in shares) at Sep. 30, 2023 128,555,644 129,062,000        
Ending balance (in shares) at Sep. 30, 2023 (506,500)   (507,000)